ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound... Show more
ENDRA Life Sciences Inc. is a medical technology company working to make clinical ultrasound more powerful for diagnosing and monitoring liver disease. Its flagship innovation, Thermo-Acoustic Enhanced UltraSound (TAEUS), aims to let clinicians measure fat content in tissue — a task traditionally handled by more expensive imaging methods such as MRI — using widely available ultrasound systems. Because the company is still in a development and early-commercialization phase, investors follow NDRA primarily for its technology pipeline and regulatory progress rather than for established sales or earnings.
ENDRA Life Sciences Inc. was incorporated as a Delaware corporation in 2007 and is headquartered in Ann Arbor, Michigan. The company listed on the Nasdaq under the ticker NDRA. It is led by Chairman and Chief Executive Officer Alexander Y. Tokman and operates with a small team in the healthcare diagnostics and medical device space.
The company's core technology is TAEUS, a next-generation enhanced-ultrasound platform. TAEUS uses a pulsed energy source, such as radio frequency, to generate ultrasonic waves deep within tissue and produce high-contrast images. The company's initial and primary application is the assessment of liver fat, a biomarker associated with metabolic diseases including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) — conditions previously referred to as NAFLD and NASH. Beyond the liver, the company has explored additional applications such as tissue-temperature monitoring during energy-based procedures.
ENDRA's business model centers on commercializing its TAEUS liver system for use at the point of patient care, working alongside the large installed base of cart-based ultrasound systems. The company has described plans for a subscription-based, recurring-revenue commercial approach, positioning its device as a lower-cost complement to MRI-based fat measurement. From a financial profile standpoint, ENDRA is a pre-revenue business: it has reported no product sales, with its market position defined by intellectual property, clinical validation efforts, and regulatory milestones rather than current revenue streams.
Investor interest in NDRA centers on the potential of its TAEUS technology to address a large and growing unmet medical need. Metabolic liver disease affects a vast global population, and the company argues that existing diagnostic approaches — including MRI and biopsy — are expensive, invasive, or impractical for widespread screening. A lower-cost, ultrasound-based alternative could appeal to primary care networks, pharmaceutical companies, and clinical research organizations seeking efficient ways to detect and monitor liver fat.
The company's strategic positioning also ties into broader trends in metabolic health, including the rapid growth of GLP-1 weight-management therapies, where liver-fat measurement may play a role in patient eligibility and monitoring. ENDRA has reported clinical validation work comparing TAEUS liver measurements against MRI-PDFF, a standard reference method, which supports its long-term growth narrative. However, these drivers remain prospective: the company must still achieve regulatory clearances and secure sufficient capital to reach commercialization.
Investing in NDRA carries significant risks common to micro-cap, development-stage medical device companies. First, ENDRA is pre-revenue and has consistently reported operating losses and a substantial accumulated deficit. The company has disclosed that management has raised substantial doubt about its ability to continue as a going concern without additional financing, and it has undertaken cost-reduction measures and explored strategic alternatives, including potential mergers or asset sales.
Regulatory risk is also material. The U.S. Food and Drug Administration (FDA) closed the company's original De Novo request in 2024, and ENDRA subsequently paused the clinical activities needed for a new submission pending additional resources. While its liver application has received CE marking in the European Union, expanding U.S. approval requires further clinical and device-testing data.
Finally, the company has pursued a Digital Asset Treasury strategy, investing in decentralized finance assets to generate non-dilutive returns. This introduces additional volatility and regulatory uncertainty into its financial results, and it has faced Nasdaq listing-compliance considerations related to stockholders' equity. Prospective investors should carefully weigh these financing, regulatory, and operational risks.
For investors looking to identify and compare opportunities across thousands of publicly traded companies and funds, Tickeron's AI Screener is an AI-powered stock and ETF discovery platform. It helps traders and investors filter the market using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable criteria. Users can efficiently screen broad universes of stocks and ETFs to surface ideas that match their own investment strategies — a useful complement to manual research on individual tickers like NDRA.
ENDRA Life Sciences (NDRA) is a distinctive early-stage player in medical imaging, distinguished by its proprietary TAEUS technology and its focus on non-invasive liver-fat measurement for metabolic disease. Its relevance to investors lies in the size of the addressable clinical need and the technology's potential to lower the cost of liver diagnostics. At the same time, the company's pre-revenue status, financing needs, and regulatory hurdles make it a high-risk profile that warrants careful due diligence.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a developer of medical imaging technology solutions
Industry MedicalSpecialties